In one paragraphArticle in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
19 authors.
Mark DavidsDepartment of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-3081-9124 Hilde HerremaDepartment of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-0112-6348 Albert K GroenDepartment of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-9942-1854 Henrike GalenkampDepartment of Public and Occupational Health, Amsterdam Public Health (APH), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-5904-3465 Aeilko ZwindermanDepartment of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-0361-3139 Joonatan PalmuDivision of Medicine, Turku University Hospital and University of Turku, Turku, Finland.ORCID 0000-0003-0059-3347 Aki HavulinnaDepartment of Computing, Turku University Hospital and University of Turku, Turku, Finland.ORCID 0000-0002-4787-8959 Teemu NiiranenDivision of Medicine, Turku University Hospital and University of Turku, Turku, Finland.ORCID 0000-0002-7394-7487 Rob KnightDepartment of Pediatrics, Department of Computer Science & Engineering, Shu Chien-Gene Lay Department of Bioengineering, and Halıcıoğlu Data Science Institute, University of California, San Diego, USA.ORCID 0000-0002-0975-9019 Yaïr AchermanDepartment of Metabolic and Bariatric Surgery, Spaarne Gasthuis, Hoofddorp, The Netherlands.ORCID 0000-0003-2787-8596 Rutger FrankenDepartment of Metabolic and Bariatric Surgery, Spaarne Gasthuis, Hoofddorp, The Netherlands.
Joanne VerheijDepartment of Pathology, UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-1283-630X Michael DukasDepartment of Pathology, Erasmus Medical Center Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0001-5064-1939 Dutch Liver Pathology Panel
Jasmohan BajajDivision of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, VA, USA.ORCID 0000-0003-4928-3681 Max NieuwdorpDepartment of Internal Medicine, section Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.ORCID 0000-0002-1926-7659 Abraham MeijnikmanTytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-6015-4656 Funding
Goblet cells and intestinal immune response in alcohol-associated liver diseaseR01AA029106 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ana Cristina Llorente Izquierdo · 2022 to 2026
$2.3MThe role of intestinal gp130 in alcohol-associated liver diseaseR21AA030654 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LLORENTE IZQUIERDO, ANA CRISTINA · 2023 to 2023
$415kNIAAA NIH HHS R01 AA029106NIAAA NIH HHS R21 AA030654
6 · The paper itselfAbstract
BACKGROUND &
aimsProton pump inhibitor (PPI) use has been associated with metabolic dysfunction associated with steatotic liver disease (MASLD) in multiple studies. While the association is confounded by various risk factors, such as BMI and age, a potential mediating factor of the microbiome has been suggested. In this study, we aimed to identify bacterial clades with the highest mediating potential and evaluate the serially mediated path through microbially derived endogenous ethanol.
methodsMicrobiome mediation analysis of PPI use and MASLD was conducted in two cohorts. In a bariatric surgery cohort (
resultsSeveral bacterial taxa, which are predominantly found in the small intestine, showed a potential role in mediating the effects of PPIs on MASLD, postprandial ethanol levels, and FLI score. The Lactobacillales order showed the strongest mediating potential across the outcomes tested in both discovery cohorts. A notable serial mediation pathway was identified, linking PPI use to MASLD via Lactobacillales abundance and postprandial plasma ethanol concentrations. The mediating role of Lactobacillales in the association between PPI use and FLI scores was confirmed in the final study cohort.
conclusionsData from multiple cross-sectional cohort studies support a mediating potential of the microbiome in the association between PPI use and hepatic steatosis, independent of alcohol consumption. The effect of PPIs on MASLD appears to be mediated mainly by increased lactic acid bacteria abundance, and is potentially, in part, serially mediated by endogenous ethanol production.
Indexed as
EthanolFatty LiverGastrointestinal MicrobiomeProton Pump InhibitorsAdultBacteriaCohort StudiesCross-Sectional StudiesFemaleHumansMaleMediation AnalysisMiddle AgedEthanolProton Pump Inhibitorsethanolfermentationgastrointestinal microbiomelactobacillalesMASLDmediation analysisobesityproton pump inhibitorssmall intestine
Identifiers
PMID42070114
PMCPMC13154942
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390